FIELD: pharmacology.
SUBSTANCE: invention refers to pharmacology, namely to drugs possessing antidepressant activity. What is presented is the use of gaulterin as an antidepressant.
EFFECT: invention makes it possible to increase efficiency of therapeutic action and to exclude occurrence of side effects.
9 cl, 1 dwg, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF PATULYTHRIN AS AN ANTIDEPRESSANT | 2022 |
|
RU2802977C1 |
| USE OF OREGANOL A WITH NEUROTROPIC ACTIVITY | 2022 |
|
RU2802871C1 |
| ANTIDEPRESSANT FOR CORRECTION OF SIDE EFFECTS FROM NEUROLEPTICS | 2019 |
|
RU2746012C2 |
| ANTIDEPRESSANT, ANXIOLYTIC, NEUROPROTECTIVE AND IMMUNOSTIMULATING AGENT | 2010 |
|
RU2429834C1 |
| 9-[2-(4-ISOPROPYLPHENOXY)ETHYL]ADENINE POSSESSING ANTIDEPRESSANT AND STRESS-RELIEVING ACTION | 2013 |
|
RU2529817C1 |
| DERIVATIVES OF 4,6-DIMETHYL-2,3-DIHYDRO-1H-PYRAZOLO[4,3-c] PYRIDINE-3-ONES AND ETHERS 2,6-DIMETHYL-4-PHENYL-HYDRAZINE NICOTINIC ACIDS AS INTERMEDIATE PRODUCTS FOR THEIR SYNTHESIS, POSSESSING ANTIDEPRESSANT AND ANXIOLYTIC POTENCY | 2007 |
|
RU2394034C2 |
| PHARMACEUTICAL COMPOSITION BASED ON BIS-(N-MONOSUCCINYL-L-SERYL-L-LYSINE) HEXAMETHYLENEDIAMIDE (GSB-106) | 2018 |
|
RU2697254C1 |
| PHARMACEUTICAL COMPOSITION BASED ON N-BUTYL-N-METHYL-1-PHENYLPYRROLO[1,2-a]PYRAZINE-3-CARBOXAMIDE | 2023 |
|
RU2811453C1 |
| PREVENTIVE OR THERAPEUTIC AGENT FOR DEPRESSION OR ANXIETY DISORDER | 2006 |
|
RU2413510C2 |
| USE OF QUERCETIN AS A DIURETIC, SALURETIC AND CREATININURETIC AGENT | 2022 |
|
RU2802833C1 |
